Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials
- 405 Downloads
Iron supplementation could improve the hematopoietic response of erythropoiesis-stimulating agents (ESAs) used for chemotherapy-induced anemia.
We performed a meta-analysis of randomized, controlled trials by comparing parenteral or oral iron and no iron, when added to ESAs in anemic cancer patients, in order to calculate the relative risk (RR) of hematopoietic response and transfusions, the time required to reach this response, and toxicity.
A total of 1,606 patients out of eight trials were available for meta-analysis. The RR of obtaining an hematopoietic response was 1.29 (P = 0.0001) with parenteral iron and 1.04 for oral iron (P = 0.59). The risk of transfusion was reduced with parenteral iron versus no iron (RR 0.77; P = 0.02) but not with oral iron (RR 0.68; P = 0.08). The time to reach hematopoietic response was 1 month shorter and no increased toxicity appeared with iron supplementation.
Overall parenteral iron reduces the risk of transfusions by 23% and increases the chance of hematopoietic response by 29% when compared with ESAs alone. On the contrary, oral iron does not increase hematopoietic response nor transfusion rate. The significance of these results is that the proportion of non-responders to ESAs will have strongly improved and quality of life and cost ameliorated.
KeywordsErythropoiesis-stimulating agents Parenteral iron Oral iron Anemia Hematopoietic response Solid tumors
Conflict of interest
I certify that no actual or potential conflict of interest in relation to this article exists.
- Bastit L, Vandebroek A, Altintas S et al (2008) Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 26(10):1611–1618PubMedCrossRefGoogle Scholar
- Hedenus M, Birgegård G, Näsman P et al (2007) Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 21(4):627–632. Epub 2007 Jan 25. Erratum in: Leukemia. 2008 Feb; 22(2):462Google Scholar
- Henry DH, Dahl NV, Ferrlecit Cancer Study Group (2004) Iron and B12 parameters in anemic cancer patients on chemotherapy presenting for epoetin alpha (EPO) therapy. Proc Am Soc Clin Oncol 23:747Google Scholar
- Henry DH, Dahl NV, Auerbach M (2007b) Is thromboembolism in cancer patients treated with erythropoietic stimulating agents related to thrombocytosis and iron restricted erythropoiesis. Blood 110. Abstract 1625Google Scholar
- Macciò A, Madeddu C, Gramignano G et al (2010) Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study. The Oncol 15(8):894–902 Epub 2010 Jul 20CrossRefGoogle Scholar
- National Comprehensive Cancer Network (2011) Clinical practice guidelines in oncology: cancer- and chemotherapy-induced anemia, V.2. 2011. http://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf. Accessed 2 Jan 2011
- Rizzo JD, Brouwers M, Hurley P et al (2010) American Society of Clinical Oncology; American Society of Hematology. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 28(33):4996–5010PubMedCrossRefGoogle Scholar
- Steensma DP, Sloan JA, Dakhil SR et al (2011) Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol 29(1):97–105PubMedCrossRefGoogle Scholar
- Vadhan-Raj S, Mirtsching B, Charu V et al (2001) Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks. J Support Oncol 1:131–138Google Scholar